331 related articles for article (PubMed ID: 27430123)
21. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing 'off' periods in patients with established Parkinson's disease.
Grosset KA; Malek N; Morgan F; Grosset DG
Eur J Neurol; 2013 Nov; 20(11):1445-50. PubMed ID: 23350812
[TBL] [Abstract][Full Text] [Related]
22. Inhaled dry powder apomorphine (VR040) for 'off ' periods in Parkinson's disease: an in-clinic double-blind dose ranging study.
Grosset KA; Malek N; Morgan F; Grosset DG
Acta Neurol Scand; 2013 Sep; 128(3):166-71. PubMed ID: 23527823
[TBL] [Abstract][Full Text] [Related]
23. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
[TBL] [Abstract][Full Text] [Related]
24. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.
Dewey RB; Maraganore DM; Ahlskog JE; Matsumoto JY
Mov Disord; 1998 Sep; 13(5):782-7. PubMed ID: 9756146
[TBL] [Abstract][Full Text] [Related]
25. Apomorphine therapy in Parkinson's disease: a review.
Haq IU; Lewitt PA; Fernandez HH
Expert Opin Pharmacother; 2007 Nov; 8(16):2799-809. PubMed ID: 17956200
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.
Neef C; van Laar T
Clin Pharmacokinet; 1999 Sep; 37(3):257-71. PubMed ID: 10511920
[TBL] [Abstract][Full Text] [Related]
27. Continuous infusion of apomorphine in patients with advanced Parkinson's disease and different degrees of functional disability.
Salazar G; Martín J; Fragoso M; Font MA
Neurologia; 2017; 32(6):407-410. PubMed ID: 26699210
[No Abstract] [Full Text] [Related]
28. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
Factor SA
Neurology; 2004 Mar; 62(6 Suppl 4):S12-7. PubMed ID: 15037666
[TBL] [Abstract][Full Text] [Related]
29. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
[TBL] [Abstract][Full Text] [Related]
30. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
Manson AJ; Turner K; Lees AJ
Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
[TBL] [Abstract][Full Text] [Related]
31. Apomorphine hydrochloride: a sublingual tablet for the OFF episodes in Parkinson's disease.
Paton DM
Drugs Today (Barc); 2021 Jan; 57(1):5-16. PubMed ID: 33594386
[TBL] [Abstract][Full Text] [Related]
32. [Proposed alternative to standard apomorphine challenge test].
Martínez-Castrillo JC; Burguera JA
Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
[TBL] [Abstract][Full Text] [Related]
33. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease.
van Laar T; Neef C; Danhof M; Roon KI; Roos RA
Mov Disord; 1996 Nov; 11(6):633-8. PubMed ID: 8914088
[TBL] [Abstract][Full Text] [Related]
34. Sublingual apomorphine solution in Parkinson's disease.
Panegyres PK; Graham SJ; Williams BK; Higgins BM; Morris JG
Med J Aust; 1991 Sep; 155(6):371-4. PubMed ID: 1921784
[TBL] [Abstract][Full Text] [Related]
35. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.
Borgemeester RWK; van Laar T
Parkinsonism Relat Disord; 2017 Dec; 45():33-38. PubMed ID: 29032012
[TBL] [Abstract][Full Text] [Related]
36. Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study.
Drapier S; Eusebio A; Degos B; Vérin M; Durif F; Azulay JP; Viallet F; Rouaud T; Moreau C; Defebvre L; Fraix V; Tranchant C; Andre K; Courbon CB; Roze E; Devos D
J Neurol; 2016 Jun; 263(6):1111-9. PubMed ID: 27060084
[TBL] [Abstract][Full Text] [Related]
37. [Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
Durif F; Deffond D; Eschalier A; Tournilhac M
Rev Neurol (Paris); 1992; 148(10):610-4. PubMed ID: 1295055
[TBL] [Abstract][Full Text] [Related]
38. [Candidate patient for treatment with continuous apomorphine infusion].
Martí MJ; Kulisevsky J
Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
[TBL] [Abstract][Full Text] [Related]
39. Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes.
Thach A; Zichlin ML; Kirson N; Yang K; Gaburo K; Pappert E; Mehta D; Williams GR
J Comp Eff Res; 2022 Mar; 11(4):285-295. PubMed ID: 35068168
[No Abstract] [Full Text] [Related]
40. [Apomorphine in the treatment of Parkinson's Disease].
Dressler D
Nervenarzt; 2005 Jun; 76(6):681-9. PubMed ID: 15592807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
